Status:
COMPLETED
PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Prostate Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A promising imaging technique involving new prostate specific membrane antigen (PSMA) positron emission tomography (PET) tracers is emerging in metastatic prostate cancer (PCa). This approach has demo...
Eligibility Criteria
Inclusion
- Ability to provide informed consent
- Metastatic prostate cancer.
- At least 18 years of age
- Standard imaging (bone scan, CT abdo/pelvis/chest) within 6 weeks of consent.
Exclusion
- \-
Key Trial Info
Start Date :
October 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2018
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT03486886
Start Date
October 2 2017
End Date
April 30 2018
Last Update
July 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada